Key Novartis AG Financials
| Company Type | Public -(Swiss: NOVN) Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Sales (mil.) | $59,375.0 |
| 2011 Employees | 123,686 |
Novartis AG Stock Quote (NYSE: NVS)(Swiss: NOVN)
| Latest 02/15/12 14:17:02 EST | Change ($) | Change (%) | High | Low |
|---|---|---|---|---|
| $56.23 |  -0.100 | -0.180 | $56.46 | $56.11 |
Quotes delayed 15 minutes for NASDAQ, 20 minues for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions. |
Novartis AG Income Statement
| Dec 11 | Dec 10 | Dec 09 | |
| Revenue | 59,375.0 | 51,561.0 | 45,103.0 |
| Cost of Goods Sold | 18,983.0 | 14,488.0 | 12,179.0 |
| Gross Profit | 40,392.0 | 37,073.0 | 32,924.0 |
| Gross Profit Margin | 68% | 71.9% | 73% |
| SG&A Expense | 18,049.0 | 15,797.0 | 14,331.0 |
| Depreciation & Amortization | -- | -- | 1,250.0 |
| Operating Income | 10,998.0 | 11,526.0 | 9,982.0 |
| Operating Margin | 18.5% | 22.4% | 22.1% |
| Nonoperating Income | 526.0 | 804.0 | 293.0 |
| Nonoperating Expenses | (751.0) | (628.0) | (353.0) |
| Income Before Taxes | 10,773.0 | 11,702.0 | 9,922.0 |
| Income Taxes | 1,528.0 | 1,733.0 | 1,468.0 |
| Net Income After Taxes | 9,245.0 | 9,969.0 | 8,454.0 |
| Continuing Operations | 9,245.0 | 9,969.0 | 8,454.0 |
| Discontinued Operations | 0.0 | 0.0 | 0.0 |
| Total Operations | 9,113.0 | 9,794.0 | 8,400.0 |
| Total Net Income | 9,113.0 | 9,794.0 | 8,400.0 |
| Net Profit Margin | 15.3% | 19% | 18.6% |
| Diluted EPS from Total Net Income | 3.78 | 4.26 | 3.69 |
| Dividends per Share | 2.00 | 1.65 | 1.71 |
All amounts in millions of US Dollars except per share amounts.
Novartis AG Balance Sheet
| Assets | Dec 11 | Dec 10 | Dec 09 |
| Current Assets | |||
| Cash | 3,709.0 | 5,319.0 | 2,894.0 |
| Net Receivables | 12,373.0 | 9,873.0 | 8,310.0 |
| Inventories | 5,930.0 | 6,093.0 | 5,830.0 |
| Other Current Assets | 2,072.0 | 5,400.0 | 16,657.0 |
| Total Current Assets | 24,084.0 | 26,685.0 | 33,691.0 |
| Net Fixed Assets | 15,627.0 | 15,840.0 | 14,075.0 |
| Other Noncurrent Assets | 77,785.0 | 80,793.0 | 47,739.0 |
| Total Assets | 117,496.0 | 123,318.0 | 95,505.0 |
| Liabilities | Dec 11 | Dec 10 | Dec 09 |
| Current Liabilities | |||
| Accounts Payable | 4,989.0 | 4,788.0 | 4,012.0 |
| Short-Term Debt | 6,344.0 | 8,627.0 | 5,313.0 |
| Other Current Liabilities | 11,815.0 | 11,243.0 | 10,145.0 |
| Total Current Liabilities | 23,148.0 | 24,658.0 | 19,470.0 |
| Long-Term Debt | 13,855.0 | 14,360.0 | 8,675.0 |
| Other Noncurrent Liabilities | 14,649.0 | 21,104.0 | 9,973.0 |
| Total Liabilities | 51,652.0 | 60,122.0 | 38,118.0 |
| Shareholder's Equity | |||
| Preferred Stock Equity | -- | -- | -- |
| Common Stock Equity | 65,844.0 | 63,196.0 | 57,387.0 |
| Total Equity | 65,844.0 | 63,196.0 | 57,387.0 |
| Shares Outstanding (thou.) | 2,406,693.9 | 2,289,445.2 | 2,274,353.4 |
All amounts in millions of US Dollars except per share amounts.
Novartis AG Cash Flow Statement
| Dec 11 | Dec 10 | Dec 09 | |
| Net Operating Cash Flow | 14,309 | 14,067 | 12,191 |
| Net Investing Cash Flow | (792.0) | (15,756.0) | (14,219.0) |
| Net Financing Cash Flow | (15,024.0) | 4,116.0 | 2,809.0 |
| Net Change in Cash | (1,610.0) | 2,425.0 | 856.0 |
| Depreciation & Amortization | 1,250.0 | ||
| Capital Expenditures | (2,387.0) | (2,232.0) | (2,733.0) |
| Cash Dividends Paid | (5,571.0) | (4,582.0) | (3,993.0) |
All amounts in millions of US Dollars except per share amounts.